G-Rex for Solid Tumors

G-Rex is the superior and market leading platform for cell therapies with solid tumor indications

Two adoptive cell therapy approaches for solid tumors and epithelial cancers have received FDA approval (Iovance Biopharmaceutical’s AMTAGVI^® and Adaptimmune’s TECELRA^® and many more under clinical development are showing promise. G-Rex has long been the gold standard in the research, development, and manufacturing of these innovation approaches.

G-Rex & TCR-T cell therapy

TCR-T cell therapy leaders choose G-Rex

Dr. Cassian Yee

MD Anderson Cancer Center

Listen to Dr. Cassian Yee from M.D. Anderson Cancer Center (an early adopter of G-Rex) give a masterclass on how TCR-T cell therapy brings hope to cancer patients.

G-Rex & Tumor Infiltrating Lymphocyte (TIL) therapy

TIL therapy leaders choose G-Rex

One of the most pivotal moments in the G-Rex’s history was the adoption and implementation of G-Rex at the National Cancer Institute’s Surgery Branch, led by the legendary Dr. Steven A Rosenberg.

The NCI Surgery Branch continues to utilize G-Rex to this today for their various adoptive cell therapy programs to bring hope to solid tumor cancer patients.

Dr. Marie-Andrée Forget

CTMC

Listen to Dr. Marie-Andree Forget from CTMC chronicle the co-evolution of TIL therapy and G-Rex.

G-Rex & Tumor-Associated Antigen (TAA) T cell therapy

T cell therapy leaders choose G-Rex

Dr. Ann Leen

Baylor College of Medicine

Listen to Dr. Ann Leen from the Baylor College of Medicine describe a recent breakthrough in pancreatic cancer through the use of a polyclonal T cell product, powered by G-Rex.